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The present and future opportunities of the RareCancer Network: an international consortium for advancement of oncologic care
The Rare Cancer Network
Abstract
To date, the Rare Cancer Network (RCN)
has initiated more than 90 studies and 54 peer-
reviewed publications were produced as a
result. The Second International Symposium of
the Rare Cancer Network recently took place in
Istanbul, Turkey on April 17-18, 2015, and
update was given on multiple currently ongo-
ing projects, while also giving room for new
proposals which will shape the direction of
future studies for the group. This companion
issue of the RCN Proceedings summarized the
findings of this meeting, while also serving as
a call for fresh projects and papers which will
continue to energize the group and advance
the oncologic science. A brief introduction to
the principles, history, and vision of the RCN
was also included. To review, the academic
year of 2014-15 marked an enormous success
for the international members of the RCN,
with the generation of 8 fully published papers
and more than 12 newly proposed topics. By
the collective efforts of all RCN members, in
the future, we look forward to the upcoming
opportunities in continuing to advance the
standard of chemo- and radiotherapeutic onco-
logic care for selected rare tumor topics. The
studies of these rare cancers often do not allow
the design and execution of prospectively
enrolled trials; however, these uncommon
malignancies do impact the humankind and
add to its suffering globally in significant ways.
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Introduction
Following the successful completion of the
First International Symposium of the Rare
Cancer Network (RCN),1 the RCN members
organized the Second International Symposium
of the RCN, generously hosted by Drs. Özyar
and Atalar at the Department of Radiation
Oncology, Acibadem Maslak Hospital in
stanbul, Turkey on April 17-18, 2015 (Figure
1). The location was particularly fitting, as 33
scientists from over 20 Turkish centers have
participated in 20 of the 54 published RCN
studies, and 5 of them were mentors of prior
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studies which had been published (prostatic
ductal carcinoma, salivary gland indolent
mucosal associated lymphoma, thyroid non-
Hodgkin’s lymphoma, pediatric nasopharyn-
geal carcinoma, and adult Langerhans cell his-
tiocytosis of bones). The continued activities
have fostered and strengthened the collabora-
tions mainly among European and American
oncologists and investigators within the RCN
(Figure 2); more Asian and Australian
alliances are possible in the future. 
For the proceedings and academic findings
of the Second International Symposium, they
will be reported in this article as a companion
and special report in the current issue of Rare
Tumors. Previously, the historical highlights of
the group have been described in detail,2
emphasizing the collegial nature of this global
network for oncologic advancement. This
report will update the findings of the First
International Symposium of the RCN to date,1
while reviewing some of the ongoing and all
newly proposed studies which were presented
in the meeting; the first 20-years’ achievement
of the RCN has been previously reported.3 For
more information regarding the RCN and our
ongoing studies, please also visit our home
webpage at www.rarecancer.net. On April 17,
2015, sessions have also been dedicated to
report and update the attending RCN members
regarding the current knowledge, recommen-
dations, and guidelines of extranodal non-
Hodgkin’s lymphoma (NHL). The RCN contri-
butions for the selected rare NHL topics were
emphasized. These lectures included an
overview of extranodal NHL (M. Arat), primary
breast lymphoma (Y. Belkacemi), primary bone
lymphomas (J. Ashman/R.C. Miller), orbital
lymphoma (M. Ozsahin), mycosis fungoides
focusing on the total skin electron-beam irra-
diation experience at a single institution (B.
Gutiérrez García), NHL of salivary glands (Y.
Anacak), testicular NHL (S. Villà), primary
spinal epidural lymphoma (R-O. Mirimanoff),
and thyroidal lymphoma (C. Onal). The updat-
ed knowledge and RCN recommendations of
the diagnosis and management of extranodal
NHL sites are the subject of a comprehensive
review paper, currently under preparation (Y.
Belkacemi).
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Figure 1. The Second International Symposium of the Rare Cancer Network, Istanbul, Turkey, April 17-18, 2015. 
Figure 2. The global geographic distribution of the Rare Cancer Network members in
2015; the countries (and cities) represented include Canada, United States of America
(Rochester, Minnesota; Scottsdale, Arizona; Jacksonville, Florida), Brazil, Chile,
Sweden, Denmark, Netherlands, United Kingdom, Belgium, Switzerland, France,
Portugal, Spain, Morocco, Greece, Israel, Turkey, Italy, Austria, Germany, China, and
Australia. 
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A brief history of the RareCancer Network
The Rare Cancer Network was first founded
by Professors Mirimanoff and Ozsahin in the
early 1990’s, radiation oncologists and scholars
practicing at the Department of Radiation
Oncology, Centre Hospitalier Universitaire
Vaudois in Lausanne, Switzerland. The admin-
istrator for the RCN is Ms. Brigitte Pointet.
The founding principle of the RCN is to provide
a platform and international resource for the
study of radiation and also other modality
treatments in rare tumors.2 We aim to collect,
analyze, and ultimately publish quality clinical
data on either a rare type of cancers in which
radiotherapy and/or chemoradiation play an
important role, or rare presentations of com-
mon cancers which are of interest to the glob-
ally practicing radiation oncologists, including
management of unusual paraneoplastic syn-
dromes.3,4 The most common tool for clinical
investigation is typically retrospective meth-
ods, however, prospectively followed protocols
and registries (J. Thariat) and case control
studies (other investigators) have been previ-
ously proposed. The announcement of new
studies must first be coordinated with the sec-
retariat office (B. Pointet) so that RCN
research activities can be tracked. To date,
more than 50 original research articles have
been published by the group, indicating the
strength of our collaborators as a result of the
ongoing research activities that have been
generated. We praise ourselves that the char-
acteristics of the RCN include rapid collection,
analysis, and dissemination of accurate scien-
tific and clinical data, informality, and also the
low cost needed for the start-up of meaningful
scientific projects and forming collaborative
groups. We are friendly in spirit, mutually con-
fident, trustworthy, and loyal to each other. For
consideration of RCN membership, please visit
www.rarecancer.net and contact Ms. Brigitte
Pointet and Professor Mahmut Ozsahin. 
Published studies and otheractive investigations
Overview and summary (T.T. Sio)
Since the last RCN meeting, 8 manuscripts
including 5 retrospective studies,5-9 2 proceed-
ings papers,1,2 and 1 editorial article have been
published.10 The collective work of these 8 pub-
lications represented 85 authors with 108
authorships total. Nine (9) authors were with
2 inclusions, and 5 authors had 3 or more
inclusions. U. Schick and colleagues reported a
series of 20 patients with adenosquamous car-
cinoma of the head and neck,9 and showed that
the overall prognosis of locoregionally
advanced cases still remained poor. In the
extraskeletal osteosarcoma study,6 Sio TT et al.
confirmed the importance of trimodality thera-
pies in the management of rare extraosseous
sarcomas, and elucidated important prognostic
factors for worse overall (stage IV, and primary
size >10 cm) and disease-free (older age, and
also primary size >10 cm) survivals. A large
series of 107 patients with small cell carcino-
ma of the urinary bladder has recently been
reported by Pasquier D et al.,8 which represent-
ed the effort of 15 RCN-affiliated medical cen-
ters across the globe. The study investigators
concluded that, in the majority of the patients
who presented with T2-4N0M0 and T2-4N1-
3M0 stages, the use of radical cystectomy
(with or without chemotherapy) and conserva-
tive, non-surgical approach resulted in compa-
rable overall and disease-free survivals; organ
preserving strategies should be encouraged for
patients afflicted with locally advanced small
cell bladder carcinoma. Weber DC et al.7 report-
ed a series of 194 patients with spinal myx-
opapillary ependymoma who were treated at
both MD Anderson Cancer Center and also
institutions from the Rare Cancer network. In
this cohort of patients, about one third of
patients experienced disease relapse after pri-
mary treatment, and not having adjuvant RT
nor gross total resection were identified as
risk factors in young patients. Along with GSF-
GETO, GETTEC/REFCOR and SFCE, Thariat J et
al.5 reported a large series of multi-institution-
al, multidisciplinary management of mainly
young adult patients with osteosarcomas of the
mandible (MOS). Having clear margins at the
time of surgery and also involving multidisci-
plinary management were essential and
impactful for successful outcome; neoadjuvant
chemotherapy should be considered for
patients presenting with intermediate or high-
grade MOS. For other RCN projects, a manu-
script for glomus tumors (Y. Lassen-Ramshad)
is currently under preparation. The extracra-
nial hemangiopericytoma/solitary fibrous
tumor project (M. Krengli) is also actively
accruing for more patient data: 4 centers have
already sent 22 cases, and at least other 6 cen-
ters are expected to collaborate in this study.
Dr. Tesanovic discussed the epidemiology and
specific issues regarding Mediterranean rare
cancers. We also extended the accrual period
for the adult medulloblastoma project (B.
Atalar) for six more months, with the hope that
more patients’ data can be accrued from addi-
tional institutions; currently, data from 115
patients from European hospitals and 66
patients from Mayo (United States) have been
successfully collected. Other ongoing studies (J. Thariat,X.S. Sun)
Differentiated non-anaplastic thyroid can-
cers (follicular, papillary, medullary, insular
types) are relatively common tumors but are
irradiated in exceptional situations only. While
irradiation of cases with radioiodine-negative
massive extrathyroidal extension is consensu-
al, other indications are highly controversial.
The sole randomized study conducted to date
on that topic was terminated early because of
slow accrual. Several retrospective studies
raise the question of irradiation for poor prog-
nostic histological variants (such as Hurtle-
oncocytic and tall cell variants), for incomplete
resection and extensive extracapsular nodal
disease. Because a randomized trial is unlikely
to be feasible, we proposed a retrospective
study, with the aim of collecting ≥400 cases
irradiated between 2000 and 2010 to assess
the role of radiation therapy in non-anaplastic
thyroid cancers, including irradiated cases and
also non-irradiated cases (T3/T4 and/or R1/R2
and/or N+ and/or and radioiodine negative
and/or recurrent). One hundred and sixty-
seven (167) patients are currently collected;
however, the publication will be launched at
200 or above to obtain adequate statistical
power which will represent one of the largest
studies to date. 
Anaplastic thyroid carcinoma (ATC) is a
rare very aggressive tumor. To date, most find-
ings about ATC have been derived from single
institution studies with limited numbers of
cohorts, with no randomized therapeutic clini-
cal trials and consequently no standard of care.
The management of ATC involves a combina-
tion of surgery (often debulking surgery),
radiotherapy, and chemotherapy. Accelerated
twice daily irradiation appears to be more effi-
cacious although it is not convenient in rou-
tine practice. Neoadjuvant chemotherapy fol-
lowed by chemoradiation may be of interest in
rapidly-growing tumors. We aim at inquiring
the current practices within the RCN network
and also determining the best combination of
multimodality strategy for ATC with regard to
extent of surgery, addition of chemotherapy,
and also radiotherapy fractionation. Currently,
152 patients have been included. We are hop-
ing to add about 50 more cases prior to the
closing of this study. 
The mainstay of treatment for salivary gland
carcinomas (SGT) is surgery. Radiotherapy is
recommended in the postoperative setting fol-
lowing incomplete surgery and/or for high
grade stage II- IV tumors, however, typically
low grade stage III-IV and also intermediate
grade stage I-II tumors are considered only on
a case-by-case basis. It is also advocated for
unresectable disease, recurrent disease, and
patients with inoperable tumors.11,12 Despite
the absence of level I-II evidence, chemothera-
py is added to radiation therapy in a number of
cases with inadequate resection margins,
extra-nodal spread, or multiple involved lymph
nodes.13 Several studies have demonstrated
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that concurrent treatment with radiotherapy
and chemotherapy is a validated approach for
certain postoperative cases of locally advanced
squamous-cell carcinoma;14,15 this strategy for
SGT has indeed been largely extrapolated from
those head and neck cancer-based data. We
assess whether the addition of chemo or tar-
geted therapies to radiation therapy either in
the postoperative or definitive setting may
improve outcomes in the management of
patients with SGT. To date, 657 patients have
been included, and 103 of those had
chemotherapy. Intermediate analyses have
trends for several histological types; however,
the statistical power remained low, especially
for the role of concomitant chemotherapy in
addition to irradiation. As a result, we will con-
tinue to open the study and call for cases in
which patients undergo chemo or targeted
therapies in addition to radiation therapy. 
New proposed studies
On April 18, 2015, twelve (12) new RCN
studies were introduced to the participating
oncologists and clinicians in the meeting.
They are reported as follows: Table 1 repre-
sents a summary of these studies and their
intended number for patient/case accruals
among the RCN-affiliated institutions. After a
Questions and Answers session, the level of
interest for each study was immediately sam-
pled among the audiences (from their institu-
tional representatives) and recorded accord-
ingly. Instant feedback was given to the men-
tors/principle investigators for each of their
individual studies. Drs. Jonathan B. Ashman
and Mahmut Ozsahin chaired this session for
the new RCN investigators. Metaplastic breast cancer (A. Arnett)
Rare breast malignancies with mixed
epithelial and mesenchymal differentiation
are termed metaplastic breast cancer (MBC,
<1% of all diagnoses). Early studies and other
case reports suggested that patients with MBC
may have worse outcomes.16,17 The tumors are
often more poorly or entirely undifferentiated
at presentation, and with a higher percentage
of triple-negative molecular phenotypes; they
tend to present with an advanced primary
tumor. The proposed study will place emphasis
on correlating the treatment modalities and
also histologic variants of MBC with patient’s
outcome, and aim to provide strategies for risk
stratification; the number of patients desired
for enrollment is higher as a result, and a large
number of institutions expressed interest in
the meeting (Table 1). Langerhans cell sarcoma (N.Paryani)
The World Health Organization (WHO) clas-
sifies Langerhans Cell Sarcoma (LCS) under
histiocytic and dendritic cell neoplasm, which
was an exceedingly rare tumor first recognized
in 1984 as malignant histiocytosis X.18 Now,
there are still fewer than 40 cases reported in
the English medical literature. LCS often pres-
ents as a high grade neoplasm and harbors an
aggressive clinical course; the survival was
very poor, with a rate of 50% at 2 years. As the
optimal treatment regimen has yet to be
defined for this rare cancer, the RCN proposes
this topic as a new study which will represents
an excellent focus for the group. Primary central nervous systemrhabdomyosarcoma (S. Ahmed) 
Primary rhabdomyosarcoma arising from
the brain or spinal cord carries very poor out-
comes, in both pediatric and also adult popula-
tions. In the modern era, immunohistopatho-
logic confirmation such as detection of
PAX3/FOXO1 fusion transcript is desired. For
primary CNS rhabdomyosarcoma, there have
only been 42 reported cases in between 1958
and 2014, with patients’ age ranging 1 to 68
years; spinal seeding happened in 4 (9.5%)
cases. The mean survival was only 9.1 months,
with only 5 (12%) patients surviving for more
than 2 years. Although there is no standard
therapy, the typical patient received surgery,
radiation therapy, or tri-modality therapy
including chemotherapy. An international RCN
study will help characterize this particularly
rare cancer and provides insight regarding the
optimal therapy plan for future patients. Adenoid cystic and squamous cellcarcinomas of the trachea (L. Moretti and K. Merrell) 
Primary tumors of the trachea are very rare
in general (both types at incidence rates of 0.1
per 100,000 capita or lower). Two particular
histologies, adenoid cystic,19 and also squa-
mous cell carcinoma, warrant further investi-
gations. Led by two international oncologists,
we aim to study these variants of tracheal can-
cers and report an updated multi-institutional
experience, as improved staging procedures,
radiotherapy techniques and chemoradiation
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Table 1. A summary of the newly proposed studies and the expected patient accrual numbers.
Leading author(s)/mentor(s)           Rare cancer topics                                        Pts desired              Level of interest among institutions
A. Arnett                                                                Metaplastic breast cancer                                                  150-200                                                      Very High
N. Paryani                                                            Langerhans cell sarcoma                                                      5-10                                                              High
S. Ahmed                                                              Primary CNS rhabdomyosarcoma                                       5-10                                                           Average
L. Moretti/P. Van Houtte                                   Tracheal adenoid cystic carcinoma                                    5-20                                                              High 
K. Merrell                                                             Tracheal squamous cell carcinoma                                    5-20                                                              High 
G. Eren                                                                Clival chordoma                                                                       5-10                                                           Average 
S. Akyürek/T. Kütük                                            Gliomatosis cerebri                                                              25-100                                                       Very High 
Y. Bölükbaşı                                                        Extraosseous Ewing’s sarcoma                                          15-50                                                             High 
D. Ç. Öksüz                                                          Extranodal NK/T-cell NHL, nasal-type                               15-50                                                             High 
F. Dincbas                                                            Dermatofibrosarcoma protuberans                                  25-100                                                       Very High 
D. Sezen                                                               Central neurocytoma                                                             5-20                                                              High 
Y. Belkacemi                                                       Primary breast NHL                                                                5-20                                                              High
CNS, central nervous system; Pts, patients; NK, Natural Killer; NHL, Non-Hodgkin’s Lymphoma. Level of interest among institutions: Average, 1-3 institutions interested in contributing patient cases to the proposal;
High, 3-8 institutions; Very high, more than 8 institutions (priority studies, in italics). 
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approaches have increased the chance of
organ preservation, with potentials to improve
quality of life in an otherwise surgically poten-
tially morbid treatment paradigm.20,21
Currently, there are no formal guidelines
across multiple American and European-based
oncologic societies and organizations. This
RCN study will assess treatment outcome and
pattern of failure, and provide insights on the
most favorable radiation dose fractionation
schedule for tracheal carcinomas.Clival chordoma (G. Eren)
Thirty-five (35) percents of chordoma are
skull based including the clivus; nevertheless,
they are so rare that it represents only less
than 1% of all intracranial tumors. Originated
from the remnants of the notochord, clival
chordoma is locally expansive and character-
ized by high recurrence rates. Clival chordoma
is resistant to systemic therapies, and surgical
gross total resection is often not possible due
to the centrally skull-based location. A study is
proposed to evaluate the effectiveness and
safety of dose-escalated radiotherapy modali-
ties including particle-based treatments such
as proton; the data collected will also focus on
treatment side effects including temporal lobe
injuries and brainstem necroses. Gliomatosis cerebri (S. Akyürekand T. Kütük)
Gliomatosis cerebri (GC) refers to a clinical
diagnosis of diffuse neoplastic glial process
which involves more than 2 anatomic lobes of
the brain parenchyma, typically with bilateral
involvement of the supratentorial structures
along with deep gray matter. Histopatho -
logically, GC is typically found to be as World
Health Organization (WHO) grade II, III, or IV
glial tumors. The epidemiology of this rare dis-
ease called GC is poorly understood, and sur-
vival is poor (median, 11-38 months). The
potential difference in therapeutic response
and prognostic impact of molecular makers
(MGMT methylation, 1p/19q co-deletion, and
IDH mutation, etc.) may be different in this
subgroup of clinically aggressive yet diffuse
gliomas; however, evidence is very limited
especially for patients who were treated in the
modern era, after the widely global adoption of
temozolomide.22,23 Due to its often fairly exten-
sive and diffuse involvement of GC, specifical-
ly, what extent of maximally safe surgery
should be performed? What are the indications
and roles of chemotherapy and also radiother-
apy (sequential vs. concurrent) in this setting?
Is there a role of whole brain radiotherapy?
How should patient factors such as perform-
ance status and age be integrated in treatment
decision making? The effective and optimal
treatment schema and choice and sequence of
modalities are clearly not well defined as of
currently, as a result, a multi-institutional
study within the context of RCN is urgently
required. This has been voted as one of the top
3 priority projects for the year, as a large num-
ber of RCN members expressed interest in
joining the current study (Table 1). Extraosseous Ewing’s sarcoma (Y.Bölükbaşı)
Although Ewing’s sarcoma may be relatively
common especially in pediatric population,
extraosseous, peripherally primitive (i.e., with
PNET differentiation) and non-central nervous
system involved cases are rare. These tumors
are aggressive in nature, with high local recur-
rent rates and often accompanied by distant
metastases.24,25 The proposed study will focus
on collecting Ewing’s sarcoma cases which are
extraskeletal in nature, and information
regarding patient and tumor characteristics
including chemotherapy responses will be
included. A careful mapping of locoregional
recurrence patterns will also be evaluated. Extranodal nasal-type NaturalKiller/T-Cell non-Hodgkin’slymphoma (D.Ç. Öksüz) 
Extranodal nasal-type Natural Killer/T-Cell
lymphoma (ENKTL) is a rare yet very aggres-
sive subtype of non-Hodgkin’s lymphoma
(NHL). It typically involves the upper aerodi-
gestive tracts including the nasal cavity and
nasopharynx, and is Epstein Barr Virus (EBV)-
related. Eighty (80) percents of the patients
presented with localized disease, i.e., extran-
odal stages I and II. Although this particular
lymphoma is relatively more common in Asia
and South America, the incidences are much
lower in Europe and also United States (<1%
of all NHL’s); the epidemiology, pattern of care
and outcome may be different.26-28
Consequently, a study was proposed to gather
patient cases with stages IE to IIE ENKTL,
focusing on a non-Asian population which may
be more prevalent amongst the RCN members’
institutions. Dermatofibrosarcoma protuberans(F. Dinçbaş) 
Dermatofibrosarcoma Protuberans, or DFSP,
is an uncommon cutaneous sarcoma (<1%)
which is exceedingly locally aggressive and
infiltrative. It tends to recur locoregionally but
rarely distantly; it is characterized by a
t(17:22) chromosomal translation. Its irregu-
lar, tentacle-like microscopic projections give
its name, Protuberans. Although the majority
of these tumors are low grade, the adjuvant
radiotherapy indications are less clear, espe-
cially in cases where close or positive margins
are obtained surgically.29 As a result, a RCN
study was proposed to study the role of neoad-
juvant and also adjuvant radiotherapy, interna-
tional patterns of care, and also elucidation of
prognostic factors such as tumor size and age.
This is a high priority study as members from
multiple institutions indicated that they have a
strong number of cases to supply (Table 1). Central neurocytoma (D. Sezen)
Central neurocytoma (CN) is a World Class
Organization (WHO) grade II neuroepithelial-
based tumor most commonly located intraven-
tricularly.30,31 They compromise of 0.1-0.5% of
all intracranial tumors, and typically occur in
patients of younger age (mean, 29 years).
Surgery remains the mainstay of treatment,
however, the role of adjuvant radiation therapy
is less clear.32 Thus, the RCN investigators pro-
posed a study to assess the clinical character-
istics, treatment outcome, and patterns of fail-
ure for patients with central neurocytoma,
focusing on the evaluation of optimal dose and
fractionation of radiotherapy (including use of
stereotactic radiosurgery) and chemotherapy
use in the modern era; prognostic factors will
also be evaluated. Implant-associated primary breastNon-Hodgkin’s lymphoma (Y.Belkacemi)
The Rare Cancer Network, led by Jeanneret-
Sozzi et al.,33 has previously published a large
series of 84 consecutive patients with primary
breast lymphoma (PBL) in 20 institutions.
They noticed that while local control and over-
all survival were fair to excellent with RT or
combined modality treatments, systemic
relapses including intracranial seeding could
still happen. Others have reported their expe-
riences with primary follicular and marginal-
zone lymphoma of the breast,34 which tended
to behave more indolently. In this proposed
study, the RCN investigators will gather PBL
cases associated with breast implants; this
tumor will typically harbor an ALK- or ALK1-
genetic mutation, and is usually histopatholog-
ically anaplastic with large cell features. The
additional series from RCN will help further
characterize the natural history of this rare
disease and also summarize the treatment
experiences (which often involve chemothera-
py and radiation) across different institutions. 
Future research directions and closing remarks
The future research directions include
involving more resident physicians and junior
faculty members globally in the participation of
RCN projects and also its leadership roles.
More promotions will be performed using
social network tools such as Facebook (B.
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Gutiérrez García). We will also expand our
presence by presenting more RCN abstracts to
ESTRO, ASTRO, and other oncologic confer-
ences globally, while also generating quality
papers in highly impactful oncologic journals.
We are also looking for opportunities to
expand our professional network and collabo-
rate with other corporate groups and institu-
tions,5,7 comprising increased efforts from
other continents such as Asia (including
Taiwan) and also Australia. Within the context
of RCN, the evolving challenges and issues
related to multi-institutional research have
been previously discussed.1 The future of the
RCN group remains bright and prosperous, as
we continue to refine and improve the roles of
radiation and also chemoradiation therapies
in the management of rare cancers throughout
the world.
The Third International Symposium of the
Rare Cancer Network will be held in Paris,
France in the spring of 2016. 
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